eravacycline

Fluorocycline · Antibiotic (Protein Synthesis Inhibitor) / Broad-spectrum anti-infective agent with FDA indications for complicated intra-abdominal infections. Also used for skin and soft-tissue infections. It is a synthetic tetracycline derivative (fluorocycline) engineered to overcome common resistance mechanisms, including efflux pumps and ribosomal protection proteins. Available only for parenteral administration. Administered intravenously. The mechanism of action involves binding to the 30S bacterial ribosome to inhibit protein synthesis, similar to other tetracyclines, but with structural modifications that enhance activity against resistant organisms. It distributes rapidly and extensively into tissues, leading to low serum levels. Excreted mostly unchanged along with a small amount of metabolites. Metabolism involves CYP3A4. For patients with severe hepatic impairment, the dosing frequency must be reduced to every 24 hours. The typical adult intravenous dosage is 1 mg/kg every 12 hours. Pediatric dosages have not been established. Adverse effects include photosensitivity, and generally, the risks associated with tetracyclines like hepatic and renal toxicity (though it has fewer renal side effects than some older tetracyclines), and effects on bone and teeth (contraindicated in children <8 and pregnancy). It did not meet noninferiority criteria in randomized trials for complicated urinary tract infections, possibly due to lack of accumulation in the urine. Drug interactions are significant as it is a substrate of CYP3A4; its concentrations are reduced by inducers (e.g., rifampin) and increased by inhibitors (e.g., itraconazole) of CYP3A4. Concomitant use with strong inducers or inhibitors should be avoided or undertaken with caution. This monograph provides a comprehensive overview of eravacycline's clinical utility, pharmacokinetic properties, dosing adjustments, and important drug interaction considerations, highlighting its role in treating multidrug-resistant infections while emphasizing the need for cautious use. The drug is considered bacteriostatic. Its enhanced activity against multidrug-resistant Gram-negatives is notable, despite its limitations in urinary tract infections. Its role as a protein synthesis inhibitor is central to its mechanism. The specific adverse effect of photosensitivity is common among tetracyclines. The careful dose adjustments in hepatic impairment are crucial for patient safety. The fact that it is not available orally and its tissue distribution pattern are important pharmacokinetic considerations. The chapter's emphasis on its use in resistant infections is a key takeaway. This comprehensive overview provides essential guidance for its clinical use. Its ability to overcome certain resistance mechanisms of older tetracyclines makes it valuable for specific, resistant infections. The lack of established pediatric dosing further limits its use in younger populations. Monitoring for photosensitivity and potential drug interactions is particularly important. The general warnings for tetracyclines regarding pregnancy and childhood also apply to eravacycline, reinforcing the need for careful patient selection. This monograph, developed from the provided text, aims to offer a complete and accurate clinical profile.